- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.07. | Modella AI and AstraZeneca link for cancer clinical development | ||
| 04.07. | AstraZeneca's Imfinzi approved in Europe for muscle-invasive bladder cancer | ||
| 04.07. | Big pharma braces for revenue headwinds as patent expiries loom | ||
| 04.07. | Biocon's Denosumab biosimilars gain EU marketing authorisation | ||
| 04.07. | Brii Biosciences and Joincare sign licence agreement for BRII-693 | ||
| 03.07. | Theratechnologies shares surge 25% amid $254m Future Pak takeover | ||
| 03.07. | UK Government reveals 10-year plan for NHS | ||
| 03.07. | BioVersys and Shionogi agree to develop ansamycin leads | ||
| 03.07. | Regeneron nabs dosing edge with Lynozyfic's FDA approval in multiple myeloma | ||
| 03.07. | Ligand's LNHC concludes merger with CHRO | ||
| 03.07. | Navigating the AI regulatory maze: Why 91% of life sciences professionals feel lost | ||
| 03.07. | Podcast: The importance of Social Determinants of Health (SDoH) | ||
| 03.07. | FDA approves Dizal's Zegfrovy to treat adults with NSCLC | ||
| 03.07. | Protecting patients' data is vital for NHS single health record system | ||
| 02.07. | Analysis shows Yeztugo approval a 'momentous step' for HIV prevention | ||
| 02.07. | Sanofi agrees to invest $25m in Adagene | ||
| 02.07. | Trump tax bill estimated to cut Medicaid spend by $1trn passes US Senate | ||
| 02.07. | Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold | ||
| 02.07. | Merck concludes SpringWorks acquisition for $3.4bn | ||
| 02.07. | Cell and gene therapy: The vital role of logistics | ||
| 02.07. | Uruguay progresses towards developing its first regulatory agency | ||
| 02.07. | EC approves Jazz Pharmaceuticals' Ziihera for biliary tract cancer | ||
| 01.07. | Oncternal sells assets for up to $68m and calls it quits | ||
| 01.07. | Sanofi's riliprubart gains ODD status from Japan's MHLW for CIDP | ||
| 01.07. | EU's Pharma Package falls short of Europe's goal of global competitiveness |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .